BioCryst Pharmaceuticals, Inc., a leading biotechnology company headquartered in Durham, North Carolina, has made significant strides in the field of small-molecule medicines. With a focus on discovering novel medications, the company has brought to market RAPIVAB, RAPIACTA, and PERAMIFLU - intravenous neuraminidase inhibitors for the treatment of acute uncomplicated influenza. Additionally, ORLADEYO, an oral serine protease inhibitor for the treatment of hereditary angioedema, is also available for patients. BioCryst is also actively developing other promising treatments such as BCX9930, an oral factor D inhibitor for complement-mediated diseases, and Galidesivir which shows potential in treating RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company's success in its research efforts is attributed to its collaborations and in-license relationships with prominent entities such as Torii Pharmaceutical Co., Ltd., Seqirus UK Limited, Shionogi & Co., Ltd., Green Cross Corporation, National Institute of Allergy and Infectious Diseases, Biomedical Advanced Research and Development Authority, the U.S. Department of Health and Human Services, The University of Alabama at Birmingham, Albert Einstein College of Medicine of Yeshiva University, and Industrial Research, Ltd. Since its founding in 1986, BioCryst Pharmaceuticals, Inc. has continued to innovate and expand its presence in the medical community. With a team of dedicated researchers and experts driving its work forward, the company is poised to make even greater strides in the future of medicine.
BioCryst Pharmaceuticals's ticker is BCRX
The company's shares trade on the NASDAQ stock exchange
They are based in Durham, North Carolina
There are 201-500 employees working at BioCryst Pharmaceuticals
It is biocryst.com
BioCryst Pharmaceuticals is in the Healthcare sector
BioCryst Pharmaceuticals is in the Biotechnology industry
The following five companies are BioCryst Pharmaceuticals's industry peers: